~~<i id='ABCAEF9BD5'><strike id='ABCAEF9BD5'><tt id='ABCAEF9BD5'><pre id='ABCAEF9BD5'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

fashion

author：knowledge 2025-09-06 03:52:53 - browse：443

The FDA building -- First Opinion coverage from STAT — Adobe

WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Free speech concerns arise in wake of journal editor Eisen's firing

focus

knowledge

hotspot

explore

entertainment

FogPharmaCEOMathaiMammenBostonGlobePhotoImportOncologystartupFogPharmajustcloseda$145millionSeriesEr

WSS

Clinical trials giant ICON acquires HumanFirst

Excited delirium, Elijah McClain, and emergency physicians

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

MoonLake credibility takes another hit with mid

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

White House calls on federal agencies to crack down on AI abuses

entertainment

fashion

focus

23andMe had bad news about my health. I wish a person had delivered it

Flu vaccine offering decent levels of protection this winter, new data show

Guidelines to prevent youth baseball injuries need more muscle

An inside look at PIPEs, biotech's buzzy new financing tool

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

George Santos makes 1st court appearance after pleading not guilty to 13 counts

ALS groups 'won't be played again' by the FDA, drug sponsors

Medicare proposal to cover medical devices draws a mixed reaction

A clever new way to fix Medicaid and graduate medical education

knowledge

UCSF medical school apologizes for unethical prisoner experiments

The Sacklers, horror, and ‘The Fall of the House of Usher’

Clinical trials giant ICON acquires HumanFirst

ALS groups 'won't be played again' by the FDA, drug sponsors

In search for therapies for solid tumors, companies turn to claudin

FogPharma raises $145 million in rare Series E round

hotspot

hotspot

explore

entertainment